Top Markets
Coin of the day
BG Medicine, Inc. BG Medicine, Inc.

BG Medicine, Inc.

BGMD
株式のランク #42481
BG Medicine, Inc. is dedicated to the development and commercialization of... BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform. Additionally, the company provides the CardioSCORE Test, a multi-analyte, biomarker-based blood test designed to assess the short-term risk of atherothrombotic cardiovascular events, such as myocardial infarction (heart attack) and ischemic stroke. BG Medicine maintains licensing, development, and commercialization agreements with major partners like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., specifically for automated versions of its galectin-3 test. Furthermore, it has forged a strategic alliance with Abbott Laboratories to jointly develop and market galectin-3 assay kits, along with their corresponding control kits and calibrators. Founded in 2000, the company was initially known as Beyond Genomics, Inc., before rebranding to BG Medicine, Inc. in October 2004. Its corporate headquarters are located in Waltham, Massachusetts.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$1.14K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 BG Medicine, Inc. (BGMD)

カテゴリー

BG Medicine, Inc.(BGMD)の利益
2026 時点の利益 TTM: 0
BG Medicine, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
BG Medicine, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益